Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1994 Jul;62(7):2761–2772. doi: 10.1128/iai.62.7.2761-2772.1994

Tumor necrosis factor alpha has a protective role in a murine model of systemic candidiasis.

A Louie 1, A L Baltch 1, R P Smith 1, M A Franke 1, W J Ritz 1, J K Singh 1, M A Gordon 1
PMCID: PMC302879  PMID: 8005666

Abstract

The role of tumor necrosis factor alpha (TNF-alpha) in host defense against systemic Candida albicans infection was evaluated in a murine model of systemic candidiasis in which uniform death occurred between 5 and 6 days after infection. TNF-alpha was first detected at 16 h postinfection and progressively increased thereafter. Peak levels (700 to 900 pg/ml) were measured in mice near death. Administration of 0.5 to 1.0 mg of polyclonal immunoglobulin G (IgG) TNF-alpha antibody (TNF-alpha Ab) to mice 2 h preinfection neutralized serum TNF-alpha for up to 30 h. However, this regimen shortened survival from a mean of 5.5 days for IgG controls to 3.4 days (P = 1.9 x 10(-12)). Semiquantitative cultures of spleen, lung, liver, and kidney conducted at 1, 2, and 3 days postinfection found colony counts of spleen and kidney to be significantly higher for TNF-alpha Ab recipients but only for the first 48 h. Administration of 1.5 and 1.0 mg of TNF-alpha Ab at 2 h before and 48 h after fungal injection, respectively, shortened the mean survival from 4.9 to 2.3 days (P = 5.2 x 10(-8)). This regimen neutralized serum TNF-alpha throughout infection. With this regimen, colony counts of all organs were significantly higher in TNF-alpha Ab recipients at 1, 2, and 3 days postinfection. Histopathologic studies showed an increase in the number and size of C. albicans foci in tissues. Peripheral leukocyte counts and inflammatory response in tissue were similar for TNF-alpha Ab and IgG sham recipients. In vitro, incubation of C. albicans with four to eight times the peak serum levels of TNF-alpha for up to 24 h did not inhibit the rate of germ tube or pseudohypha formation. Thus, TNF-alpha that was produced during infection with C. albicans augmented host resistance against this organism and prolonged survival. The protective effect of TNF-alpha was not mediated by increased leukocytes in blood or tissues nor by a direct anticandidal effect of TNF-alpha. This study suggests that the administration of exogenous TNF-alpha may enhance host resistance against systemic C. albicans infection and may improve host survival.

Full text

PDF
2761

Images in this article

2766Image
on p.2766
2767Image
on p.2767
2768Image
on p.2768

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aderka D., Holtmann H., Toker L., Hahn T., Wallach D. Tumor necrosis factor induction by Sendai virus. J Immunol. 1986 Apr 15;136(8):2938–2942. [PubMed] [Google Scholar]
  2. Allendoerfer R., Magee D. M., Smith J. G., Bonewald L., Graybill J. R. Induction of tumor necrosis factor-alpha in murine Candida albicans infection. J Infect Dis. 1993 May;167(5):1168–1172. doi: 10.1093/infdis/167.5.1168. [DOI] [PubMed] [Google Scholar]
  3. Anaissie E., Bodey G. P., Kantarjian H., David C., Barnett K., Bow E., Defelice R., Downs N., File T., Karam G. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med. 1991 Aug;91(2):142–150. doi: 10.1016/0002-9343(91)90006-j. [DOI] [PubMed] [Google Scholar]
  4. Barral-Netto M., Badaró R., Barral A., Almeida R. P., Santos S. B., Badaró F., Pedral-Sampaio D., Carvalho E. M., Falcoff E., Falcoff R. Tumor necrosis factor (cachectin) in human visceral leishmaniasis. J Infect Dis. 1991 Apr;163(4):853–857. doi: 10.1093/infdis/163.4.853. [DOI] [PubMed] [Google Scholar]
  5. Bessler H., Gilgal R., Djaldetti M., Zahavi I. Effect of pentoxifylline on the phagocytic activity, cAMP levels, and superoxide anion production by monocytes and polymorphonuclear cells. J Leukoc Biol. 1986 Dec;40(6):747–754. doi: 10.1002/jlb.40.6.747. [DOI] [PubMed] [Google Scholar]
  6. Beutler B., Mahoney J., Le Trang N., Pekala P., Cerami A. Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J Exp Med. 1985 May 1;161(5):984–995. doi: 10.1084/jem.161.5.984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bodey G. P. Candidiasis in cancer patients. Am J Med. 1984 Oct 30;77(4D):13–19. [PubMed] [Google Scholar]
  8. Bodey G. P. Fungal infections complicating acute leukemia. J Chronic Dis. 1966 Jun;19(6):667–687. doi: 10.1016/0021-9681(66)90066-x. [DOI] [PubMed] [Google Scholar]
  9. Bross J., Talbot G. H., Maislin G., Hurwitz S., Strom B. L. Risk factors for nosocomial candidemia: a case-control study in adults without leukemia. Am J Med. 1989 Dec;87(6):614–620. doi: 10.1016/s0002-9343(89)80392-4. [DOI] [PubMed] [Google Scholar]
  10. Cleary J. D., Chapman S. W., Nolan R. L. Pharmacologic modulation of interleukin-1 expression by amphotericin B-stimulated human mononuclear cells. Antimicrob Agents Chemother. 1992 May;36(5):977–981. doi: 10.1128/aac.36.5.977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Daimond R. D., Krzesicki R. Mechanisms of attachment of neutrophils to Candida albicans pseudohyphae in the absence of serum, and of subsequent damage to pseudohyphae by microbicidal processes of neutrophils in vitro. J Clin Invest. 1978 Feb;61(2):360–369. doi: 10.1172/JCI108946. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Diamond R. D., Haudenschild C. C. Monocyte-mediated serum-independent damage to hyphal and pseudohyphal forms of Candida albicans in vitro. J Clin Invest. 1981 Jan;67(1):173–182. doi: 10.1172/JCI110010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Djeu J. Y., Blanchard D. K., Halkias D., Friedman H. Growth inhibition of Candida albicans by human polymorphonuclear neutrophils: activation by interferon-gamma and tumor necrosis factor. J Immunol. 1986 Nov 1;137(9):2980–2984. [PubMed] [Google Scholar]
  14. Djeu J. Y., Blanchard D. K., Richards A. L., Friedman H. Tumor necrosis factor induction by Candida albicans from human natural killer cells and monocytes. J Immunol. 1988 Dec 1;141(11):4047–4052. [PubMed] [Google Scholar]
  15. Djeu J. Y. Role of tumor necrosis factor and colony-stimulating factors in phagocyte function against Candida albicans. Diagn Microbiol Infect Dis. 1990 Sep-Oct;13(5):383–386. doi: 10.1016/0732-8893(90)90007-i. [DOI] [PubMed] [Google Scholar]
  16. Dofferhoff A. S., Esselink M. T., de Vries-Hospers H. G., van Zanten A., Bom V. J., Weits J., Vellenga E. The release of endotoxin from antibiotic-treated Escherichia coli and the production of tumour necrosis factor by human monocytes. J Antimicrob Chemother. 1993 Mar;31(3):373–384. doi: 10.1093/jac/31.3.373. [DOI] [PubMed] [Google Scholar]
  17. Ferrante A. Tumor necrosis factor alpha potentiates neutrophil antimicrobial activity: increased fungicidal activity against Torulopsis glabrata and Candida albicans and associated increases in oxygen radical production and lysosomal enzyme release. Infect Immun. 1989 Jul;57(7):2115–2122. doi: 10.1128/iai.57.7.2115-2122.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Flick D. A., Gifford G. E. Comparison of in vitro cell cytotoxic assays for tumor necrosis factor. J Immunol Methods. 1984 Mar 30;68(1-2):167–175. doi: 10.1016/0022-1759(84)90147-9. [DOI] [PubMed] [Google Scholar]
  19. Gaines J. D., Remington J. S. Disseminated candidiasis in the surgical patient. Surgery. 1972 Nov;72(5):730–736. [PubMed] [Google Scholar]
  20. Girardin E., Grau G. E., Dayer J. M., Roux-Lombard P., Lambert P. H. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med. 1988 Aug 18;319(7):397–400. doi: 10.1056/NEJM198808183190703. [DOI] [PubMed] [Google Scholar]
  21. Gondal J. A., Swartz R. P., Rahman A. Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob Agents Chemother. 1989 Sep;33(9):1544–1548. doi: 10.1128/aac.33.9.1544. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Grant S. M., Clissold S. P. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs. 1989 Mar;37(3):310–344. doi: 10.2165/00003495-198937030-00003. [DOI] [PubMed] [Google Scholar]
  23. Hammerschmidt D. E., Kotasek D., McCarthy T., Huh P. W., Freyburger G., Vercellotti G. M. Pentoxifylline inhibits granulocyte and platelet function, including granulocyte priming by platelet activating factor. J Lab Clin Med. 1988 Aug;112(2):254–263. [PubMed] [Google Scholar]
  24. Havell E. A. Production of tumor necrosis factor during murine listeriosis. J Immunol. 1987 Dec 15;139(12):4225–4231. [PubMed] [Google Scholar]
  25. Hesse D. G., Tracey K. J., Fong Y., Manogue K. R., Palladino M. A., Jr, Cerami A., Shires G. T., Lowry S. F. Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet. 1988 Feb;166(2):147–153. [PubMed] [Google Scholar]
  26. Hinshaw L. B., Tekamp-Olson P., Chang A. C., Lee P. A., Taylor F. B., Jr, Murray C. K., Peer G. T., Emerson T. E., Jr, Passey R. B., Kuo G. C. Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha). Circ Shock. 1990 Mar;30(3):279–292. [PubMed] [Google Scholar]
  27. Horn R., Wong B., Kiehn T. E., Armstrong D. Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy. Rev Infect Dis. 1985 Sep-Oct;7(5):646–655. doi: 10.1093/clinids/7.5.646. [DOI] [PubMed] [Google Scholar]
  28. Jeremias J., Kalo-Klein A., Witkin S. S. Individual differences in tumour necrosis factor and interleukin-1 production induced by viable and heat-killed Candida albicans. J Med Vet Mycol. 1991;29(3):157–163. doi: 10.1080/02681219180000261. [DOI] [PubMed] [Google Scholar]
  29. Jupin C., Parant M., Chedid L. Involvement of reactive oxygen metabolites in the candidacidal activity of human neutrophils stimulated by muramyl dipeptide or tumor necrosis factor. Immunobiology. 1989 Nov;180(1):68–79. doi: 10.1016/S0171-2985(89)80031-2. [DOI] [PubMed] [Google Scholar]
  30. Karabinis A., Hill C., Leclercq B., Tancrède C., Baume D., Andremont A. Risk factors for candidemia in cancer patients: a case-control study. J Clin Microbiol. 1988 Mar;26(3):429–432. doi: 10.1128/jcm.26.3.429-432.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Komshian S. V., Uwaydah A. K., Sobel J. D., Crane L. R. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis. 1989 May-Jun;11(3):379–390. doi: 10.1093/clinids/11.3.379. [DOI] [PubMed] [Google Scholar]
  32. Kullberg B. J., van 't Wout J. W., Poell R. J., van Furth R. Combined effect of fluconazole and recombinant human interleukin-1 on systemic candidiasis in neutropenic mice. Antimicrob Agents Chemother. 1992 Jun;36(6):1225–1229. doi: 10.1128/aac.36.6.1225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Lopez-Berestein G., Bodey G. P., Fainstein V., Keating M., Frankel L. S., Zeluff B., Gentry L., Mehta K. Treatment of systemic fungal infections with liposomal amphotericin B. Arch Intern Med. 1989 Nov;149(11):2533–2536. [PubMed] [Google Scholar]
  34. Maksymiuk A. W., Thongprasert S., Hopfer R., Luna M., Fainstein V., Bodey G. P. Systemic candidiasis in cancer patients. Am J Med. 1984 Oct 30;77(4D):20–27. [PubMed] [Google Scholar]
  35. Marks J. D., Marks C. B., Luce J. M., Montgomery A. B., Turner J., Metz C. A., Murray J. F. Plasma tumor necrosis factor in patients with septic shock. Mortality rate, incidence of adult respiratory distress syndrome, and effects of methylprednisolone administration. Am Rev Respir Dis. 1990 Jan;141(1):94–97. doi: 10.1164/ajrccm/141.1.94. [DOI] [PubMed] [Google Scholar]
  36. Nakane A., Minagawa T., Kato K. Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection. Infect Immun. 1988 Oct;56(10):2563–2569. doi: 10.1128/iai.56.10.2563-2569.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Nolla-Salas J., León C., Torres-Rodríguez J. M., Martín E., Sitges-Serra A. Treatment of candidemia in critically ill surgical patients with intravenous fluconazole. Clin Infect Dis. 1992 Apr;14(4):952–954. doi: 10.1093/clinids/14.4.952. [DOI] [PubMed] [Google Scholar]
  38. Opal S. M., Cross A. S., Kelly N. M., Sadoff J. C., Bodmer M. W., Palardy J. E., Victor G. H. Efficacy of a monoclonal antibody directed against tumor necrosis factor in protecting neutropenic rats from lethal infection with Pseudomonas aeruginosa. J Infect Dis. 1990 Jun;161(6):1148–1152. doi: 10.1093/infdis/161.6.1148. [DOI] [PubMed] [Google Scholar]
  39. Pisa P., Gennene M., Söder O., Ottenhoff T., Hansson M., Kiessling R. Serum tumor necrosis factor levels and disease dissemination in leprosy and leishmaniasis. J Infect Dis. 1990 May;161(5):988–991. doi: 10.1093/infdis/161.5.988. [DOI] [PubMed] [Google Scholar]
  40. Riipi L., Carlson E. Tumor necrosis factor (TNF) is induced in mice by Candida albicans: role of TNF in fibrinogen increase. Infect Immun. 1990 Sep;58(9):2750–2754. doi: 10.1128/iai.58.9.2750-2754.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Shalaby M. R., Aggarwal B. B., Rinderknecht E., Svedersky L. P., Finkle B. S., Palladino M. A., Jr Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factors. J Immunol. 1985 Sep;135(3):2069–2073. [PubMed] [Google Scholar]
  42. Smith J. G., Magee D. M., Williams D. M., Graybill J. R. Tumor necrosis factor-alpha plays a role in host defense against Histoplasma capsulatum. J Infect Dis. 1990 Dec;162(6):1349–1353. doi: 10.1093/infdis/162.6.1349. [DOI] [PubMed] [Google Scholar]
  43. Solomkin J. S., Flohr A., Simmons R. L. Candida infections in surgical patients. Dose requirements and toxicity of amphotericin B. Ann Surg. 1982 Feb;195(2):177–185. doi: 10.1097/00000658-198202000-00010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Steinshamn S., Waage A. Tumor necrosis factor and interleukin-6 in Candida albicans infection in normal and granulocytopenic mice. Infect Immun. 1992 Oct;60(10):4003–4008. doi: 10.1128/iai.60.10.4003-4008.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Strieter R. M., Remick D. G., Ward P. A., Spengler R. N., Lynch J. P., 3rd, Larrick J., Kunkel S. L. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun. 1988 Sep 30;155(3):1230–1236. doi: 10.1016/s0006-291x(88)81271-3. [DOI] [PubMed] [Google Scholar]
  46. Sullivan G. W., Carper H. T., Novick W. J., Jr, Mandell G. L. Inhibition of the inflammatory action of interleukin-1 and tumor necrosis factor (alpha) on neutrophil function by pentoxifylline. Infect Immun. 1988 Jul;56(7):1722–1729. doi: 10.1128/iai.56.7.1722-1729.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Tracey K. J., Beutler B., Lowry S. F., Merryweather J., Wolpe S., Milsark I. W., Hariri R. J., Fahey T. J., 3rd, Zentella A., Albert J. D. Shock and tissue injury induced by recombinant human cachectin. Science. 1986 Oct 24;234(4775):470–474. doi: 10.1126/science.3764421. [DOI] [PubMed] [Google Scholar]
  48. Tracey K. J., Fong Y., Hesse D. G., Manogue K. R., Lee A. T., Kuo G. C., Lowry S. F., Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987 Dec 17;330(6149):662–664. doi: 10.1038/330662a0. [DOI] [PubMed] [Google Scholar]
  49. Tracey K. J., Vlassara H., Cerami A. Cachectin/tumour necrosis factor. Lancet. 1989 May 20;1(8647):1122–1126. doi: 10.1016/s0140-6736(89)92394-5. [DOI] [PubMed] [Google Scholar]
  50. Van't Wout J. W., Van der Meer J. W., Barza M., Dinarello C. A. Protection of neutropenic mice from lethal Candida albicans infection by recombinant interleukin 1. Eur J Immunol. 1988 Jul;18(7):1143–1146. doi: 10.1002/eji.1830180728. [DOI] [PubMed] [Google Scholar]
  51. Waage A., Halstensen A., Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet. 1987 Feb 14;1(8529):355–357. doi: 10.1016/s0140-6736(87)91728-4. [DOI] [PubMed] [Google Scholar]
  52. Wey S. B., Mori M., Pfaller M. A., Woolson R. F., Wenzel R. P. Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med. 1989 Oct;149(10):2349–2353. [PubMed] [Google Scholar]
  53. von Asmuth E. J., Maessen J. G., van der Linden C. J., Buurman W. A. Tumour necrosis factor alpha (TNF-alpha) and interleukin 6 in a zymosan-induced shock model. Scand J Immunol. 1990 Oct;32(4):313–319. doi: 10.1111/j.1365-3083.1990.tb02925.x. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES